Proprietary Scales

BAC is a user-friendly electronic cognitive assessment battery with improved sensitivity to impairment.

BAC is quick and easy to administer while preserving the human interaction of traditional neurocognitive testing that is necessary for impaired populations. The electronic BAC Assessment provides investigators with meaningful results while reducing rater and patient burden.

The tablet-based Brief Assessment of Cognition in Schizophrenia is a proprietary measure designed by WCG experts.

The BAC Measures Performance Across Multiple Cognitive Domains:

• Verbal Memory
• Processing Speed
• Working Memory
• Verbal Fluency
• Motor Function
• Executive Function

Key benefits of the BAC:

• Scientifically validated
• Large database of available normative data
• Alternate forms for repeated testing
• Automated response capture and scoring
• High reliability and sensitivity to impairment
• Available in multiple languages

The VRFCAT is a tablet-based task that simulates key instrumental activities of daily living (iADLS) in a realistic and interactive virtual environment.

With demonstrated sensitivity to basic functional capacity deficits, the VRFCAT was developed to improve clinical trials by detecting functionally meaningful improvements in patients’ everyday lives.

The VRFCAT has numerous advantages over conventional assessments, and meets the highest psychometric and regulatory standards, with strong support from industry sponsors, NIH and FDA as a functional co-primary outcome measure.

The VRFCAT has officially been accepted into the FDA’s COA Qualification Program as a measure of functional capacity for schizophrenia treatment trials. This FDA program is intended to qualify drug development tools that can be relied on to have a specific interpretation and application in any drug development program and regulatory review. The FDA also awarded a grant to conduct further research on the VRFCAT.

Advantages of the VRFCAT:

• Scientifically validated
• Accurate, performance-based results
• Integrated data capture
• Alternate forms for repeated testing
• Eases administrator burden

• Well-tolerated by patients
• Available in multiple languages and culturally adapted environments
• Fast, responsive 24/7 technical support
• FDA 21 CFR Part 11 Compliant

The Schizophrenia Cognition Rating Scale (SCoRS) is a 20-item interview-based clinical assessment available on tablet or via pen-and-paper that evaluates cognitive deficits and the degree to which these deficits impair patients’ day-to-day functioning. It was originally developed in 2001 at Duke University Medical Center by Dr. Richard Keefe and is licensed through WCG. The SCoRS is used in registration-level clinical trials, academic research and in clinical settings.

The SCoRS contains questions about the patient’s ability to manage cognitively demanding, functionally relevant, everyday tasks such as conversations, watching television and using electronic devices.

The items were developed to assess the following cognitive domains:

• Attention
• Memory
• Working Memory
• Language Production
• Reasoning
• Problem Solving
• Motor Skills
• Social Cognition

As an interview-based assessment of cognition, the SCoRS meets the criteria established by the FDA-NIMH-MATRICS panel for co-primary outcome measures for cognitive enhancement trials in schizophrenia. Contact us today to learn more about the Schizophrenia Cognition Rating Scale.